What is a stock summary page? Click here for an overview.
Business Description
GT Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US36254L1008
Description
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 131.7 | |||||
| Equity-to-Asset | -0.4 | |||||
| Debt-to-Equity | -0.02 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 51.6 | |||||
| 3-Year EPS without NRI Growth Rate | 50.8 | |||||
| 3-Year FCF Growth Rate | 25.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 38.49 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.77 | |||||
| 9-Day RSI | 49.73 | |||||
| 14-Day RSI | 49.8 | |||||
| 3-1 Month Momentum % | -27.33 | |||||
| 6-1 Month Momentum % | 7.92 | |||||
| 12-1 Month Momentum % | -50.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.72 | |||||
| Quick Ratio | 0.72 | |||||
| Cash Ratio | 0.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.9 | |||||
| Shareholder Yield % | -48.67 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -351.49 | |||||
| ROA % | -148.63 | |||||
| ROIC % | -3089.03 | |||||
| 3-Year ROIIC % | 51989.16 | |||||
| ROC (Joel Greenblatt) % | -23644.31 | |||||
| ROCE % | -351.49 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 0.29 | |||||
| EV-to-EBITDA | 0.29 | |||||
| EV-to-FCF | 0.3 | |||||
| Earnings Yield (Greenblatt) % | 344.83 | |||||
| FCF Yield % | -216.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GTBP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GT Biopharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -7 | ||
| Beta | 0.96 | ||
| 3-Year Sharpe Ratio | -1.36 | ||
| 3-Year Sortino Ratio | -1.49 | ||
| Volatility % | 67.79 | ||
| 14-Day RSI | 49.8 | ||
| 14-Day ATR ($) | 0.222491 | ||
| 20-Day SMA ($) | 2.394505 | ||
| 12-1 Month Momentum % | -50.03 | ||
| 52-Week Range ($) | 1.72 - 10.6599 | ||
| Shares Outstanding (Mil) | 2.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GT Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GT Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
GT Biopharma Inc Frequently Asked Questions
What is GT Biopharma Inc(GTBP)'s stock price today?
The current price of GTBP is $2.35. The 52 week high of GTBP is $10.66 and 52 week low is $1.72.
When is next earnings date of GT Biopharma Inc(GTBP)?
The next earnings date of GT Biopharma Inc(GTBP) is 2025-05-15 Est..
Does GT Biopharma Inc(GTBP) pay dividends? If so, how much?
GT Biopharma Inc(GTBP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers